N-(p-coumaroyl)serotonin: structure in first source [MeSH]
N6-cis-p-Coumaroylserotonin : no description available [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 5458879 |
| CHEMBL ID | 1760547 |
| SCHEMBL ID | 471921 |
| CHEBI ID | 175113 |
| MeSH ID | M0295845 |
| Synonym |
|---|
| (e)-n-[2-(5-hydroxy-1h-indol-3-yl)ethyl]-3-(4-hydroxyphenyl)prop-2-enamide |
| 201301-83-9 |
| n6-cis-p-coumaroylserotonin |
| CHEBI:175113 |
| 5-hydroxy-n-feruloyltryptamine |
| serotonin ii, n (p-coumaroyl)- |
| nsc-369503 |
| tryptamine, 5-hydroxy-n- |
| NSC369503 , |
| 68573-24-0 |
| p-coumaric acid serotonin amide |
| p-coumaroylserotonin |
| CHEMBL1760547 , |
| n-p-coumaroyl serotonin |
| bdbm50341135 |
| unii-iuc27q8ach |
| 2-propenamide, n-(2-(5-hydroxy-1h-indol-3-yl)ethyl)-3-(4-hydroxyphenyl)-, (2e)- |
| iuc27q8ach , |
| coumaroylserotonin 98 |
| n-coumaroyl serotonin |
| p-c-serotonin |
| 4-coumaroylserotonin |
| 2-propenamide, n-(2-(5-hydroxy-1h-indol-3-yl)ethyl)-3-(4-hydroxyphenyl)-, (e)- |
| trans-n-(p-coumaroyl)serotonin |
| n-coumaroyl serotonin [inci] |
| n-[2-(5-hydroxy-1h-indol-3-yl)ethyl]-3-(4-hydroxyphenyl)-2-propenamide |
| n-(p-coumaroyl) serotonin |
| nsc 369503 |
| (e)-n-(2-(5-hydroxy-1h-indol-3-yl)ethyl)-3-(4-hydroxyphenyl)acrylamide |
| WLZPAFGVOWCVMG-FPYGCLRLSA-N |
| SCHEMBL471921 |
| DTXSID10173951 |
| (2e)-n-[2-(5-hydroxy-1h-indol-3-yl)ethyl]-3-(4-hydroxyphenyl)prop-2-enamide |
| n-(p-coumaroyl)serotonin |
| n-[2-(5-hydroxy-1h-indol-3-yl)ethyl]-p-coumaramide |
| Q27280901 |
| n-(2-(5-hydroxy-1h-indol-3-yl)ethyl)-3-(4-hydroxyphenyl)acrylamide |
| HY-129440 |
| n-(p-oumaroyl) serotonin |
| AS-81895 |
| CS-0105540 |
| Z3247251374 |
| Class | Description |
|---|---|
| hydroxyindoles | Any member of the class of indoles carrying at least one hydroxy group. |
| carboxamide | An amide of a carboxylic acid, having the structure RC(=O)NR2. The term is used as a suffix in systematic name formation to denote the -C(=O)NH2 group including its carbon atom. |
n-(p-coumaroyl)serotonin is involved in 1 pathway(s), involving a total of 0 unique proteins and 34 unique compounds
| Pathway | Proteins | Compounds |
|---|---|---|
| hydroxycinnamic acid serotonin amides biosynthesis | 0 | 17 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Polyphenol oxidase 2 | Agaricus bisporus | IC50 | 8.8000 | AID590195 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | EC50 | 1.2000 | AID1564246 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1367568 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs by Griess assay | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23 ISSN: 1464-3405 | Inhibitory effect of moschamine isolated from Carthamus tinctorius on LPS-induced inflammatory mediators via AP-1 and STAT1/3 inactivation in RAW 264.7 macrophages. |
| AID590194 | Antioxidant activity assessed as DPPH radical scavenging activity by spectrophotometry | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7 ISSN: 1464-3405 | Synthesis and structure-activity relationships of phenylpropanoid amides of serotonin on tyrosinase inhibition. |
| AID1367569 | Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability up to 200 uM measured after 24 hrs in presence of LPS by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23 ISSN: 1464-3405 | Inhibitory effect of moschamine isolated from Carthamus tinctorius on LPS-induced inflammatory mediators via AP-1 and STAT1/3 inactivation in RAW 264.7 macrophages. |
| AID652653 | Inhibition of COX2 at 400 uM after 5 mins by spectrophotometric analysis | 2012 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7 ISSN: 1464-3405 | N-Caffeoyl serotonin as selective COX-2 inhibitor. |
| AID652652 | Inhibition of COX1 at 400 uM after 5 mins by spectrophotometric analysis | 2012 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7 ISSN: 1464-3405 | N-Caffeoyl serotonin as selective COX-2 inhibitor. |
| AID590195 | Inhibition of mushroom tyrosinase after 25 mins by spectrophotometry | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7 ISSN: 1464-3405 | Synthesis and structure-activity relationships of phenylpropanoid amides of serotonin on tyrosinase inhibition. |
| AID1367591 | Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability up to 200 uM measured after 24 hrs in absence of LPS by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23 ISSN: 1464-3405 | Inhibitory effect of moschamine isolated from Carthamus tinctorius on LPS-induced inflammatory mediators via AP-1 and STAT1/3 inactivation in RAW 264.7 macrophages. |
| AID1564246 | Inhibition of recombinant human MAOB using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition and measured after 20 mins by fluorescence spectrophotometry | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Cinnamamide: An insight into the pharmacological advances and structure-activity relationships. |
| AID1367567 | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production pretreated for 1 hr followed by LPS addition measured after 24 hrs | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23 ISSN: 1464-3405 | Inhibitory effect of moschamine isolated from Carthamus tinctorius on LPS-induced inflammatory mediators via AP-1 and STAT1/3 inactivation in RAW 264.7 macrophages. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (90.91%) | 84.16% |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrocytoma, Grade IV | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Atherogenesis | 0 | 2006 | 2009 | 16.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 | |
| Atherosclerosis | 0 | 2006 | 2009 | 16.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 | |
| Benign Neoplasms, Brain | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Body Weight | 0 | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Brain Neoplasms | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Elevated Cholesterol | 0 | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Glioblastoma | 0 | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Hypercholesterolemia | 0 | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Muscle Contraction | 0 | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |